de Oliveira Rodrigo Bueno, Barreto Fellype Carvalho, Custódio Melani Ribeiro, Gueiros José Edvanilson Barros, Neves Carolina Lara, Karohl Cristina, Sampaio Elisa de Albuquerque, da Costa Rackel Mota, Canziani Maria Eugênia Fernandes, Moysés Rosa Maria Afonso, de Carvalho Aluízio Barbosa, Jorgetti Vanda
Universidade de São Paulo.
Pontifícia Universidade Católica do Paraná.
J Bras Nefrol. 2014 Jul-Sep;36(3):352-9. doi: 10.5935/0101-2800.20140050.
Mineral bone disorder (MBD) is a common condition in chronic kidney disease (CKD) patients and causes significant morbidity and mortality. Data involving prevalence of alterations in bone histological patterns, impact of different treatments and its repercussion in outcomes, such as bone fractures, hospitalization, cardiovascular disease and mortality, are scarce. Data bank registry can be a valuable tool to understand epidemiological aspects of MBD CKD. The Brazilian Registry of Bone Biopsy (REBRABO) will be a national registry, coordinating by the Brazilian Society of Nephrology - Committee of MBD-CKD.
To describe REBRABO's design, elements of data and methodology.
Will be an online national observational and multicentric data registry divided in two phases (retrospective, 1st phase) and prospective (2nd phase), including information from bone tissue histomorphometric analysis and demographics, clinical and laboratorial data from CKD-MBD patients.
The REBRABO's first phase will explore data on demographics, clinical, laboratorial and bone histomorphometric analysis data from January/1986 to December/2013. The first RESULTS are expected in early 2015.
Studies in the field of CKD-MBD are needed, particularly those analyzing its prevalence, associations between demographic, clinical, histological parameters, and major outcomes. The REBRABO will be a unique retrospective and prospective research platform including bone biopsy data in CKD-MBD patients.
矿物质骨病（MBD）是慢性肾脏病（CKD）患者的常见病症，可导致显著的发病率和死亡率。关于骨组织学模式改变的患病率、不同治疗方法的影响及其对骨折、住院、心血管疾病和死亡率等结局的影响的数据稀缺。数据库登记可成为了解CKD-MBD流行病学特征的宝贵工具。巴西骨活检登记处（REBRABO）将是一个全国性登记处，由巴西肾脏病学会-MBD-CKD委员会协调。
描述REBRABO的设计、数据要素和方法。
将是一个在线的全国性观察性多中心数据登记处，分为两个阶段（回顾性，第一阶段）和前瞻性（第二阶段），包括来自骨组织形态计量学分析的信息以及CKD-MBD患者的人口统计学、临床和实验室数据。
REBRABO的第一阶段将探索1986年1月至2013年12月期间的人口统计学、临床、实验室和骨组织形态计量学分析数据。预计2015年初得出首批结果。
需要在CKD-MBD领域开展研究，尤其是那些分析其患病率、人口统计学、临床、组织学参数与主要结局之间关联的研究。REBRABO将是一个独特的回顾性和前瞻性研究平台，包括CKD-MBD患者的骨活检数据。
